Treatment methods using anti-CD22 antibodies

Abstract

The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).

1 . A method for treating a human patient diagnosed with a B-cell malignancy, comprising: 
 (a) administering to said human patient an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or specifically binding to an epitope within the first two Ig-like domains, of native human CD22 (hCD22) of SEQ ID NO: 1, and    (b) monitoring the response of said malignancy to said treatment.    
     
     
         2 . The method of  claim 1 , wherein said antibody binds to the same epitope of an antibody produced from a hybridoma selected from the group consisting of ATCC® Accession Nos. HB11347, HB11349, PTA-7491, PTA-7492, PTA-7493 and PTA-7427.  
     
     
         3 . The method of  claim 2 , wherein the hybridoma is ATCC® Accession No. HB11347, HB11349, PTA-7491 or PTA-7427.  
     
     
         4 . The method of  claim 3 , wherein the hybridoma is ATCC® Accession No. HB11347.  
     
     
         5 . The method of  claim 3 , wherein the hybridoma is ATCC® Accession No. HB7491.  
     
     
         6 . The method of  claim 1 , wherein said antibody blocks CD22 binding to its ligand by at least about 70%.  
     
     
         7 . The method of  claim 1 , wherein said antibody blocks CD22 binding to its ligand by at least about 80%.  
     
     
         8 . (canceled)  
     
     
         9 . The method of  claim 1 , wherein said B-cell malignancy is selected from the group consisting of B-cell subtype of non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hairy cell leukemia, and prolymphocytic leukemia.  
     
     
         10 .- 16 . (canceled)  
     
     
         17 . The method of  claim 1 , wherein said antibody is a fragment of a complete antibody and is effective to specifically bind to the first two Ig-like domains, or to specifically bind to an epitope within the first two Ig-like domains, of native human CD22 (hCD22) of SEQ ID NO: 1.  
     
     
         18 . The method of  claim 17 , wherein said antibody is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments, wherein said multispecific antibodies bind antigens selected from CD3, CD16, CD19, CD20, CD28, CD52, CD64, and CD89 in addition to CD22.  
     
     
         19 . The method of  claim 1 , wherein said antibody has an additional antigen-specificity for an antigen selected from CD3, CD16, CD19, CD20, CD28, CD52, CD 64, and CD89.  
     
     
         20 . The method of  claim 19 , wherein said antibody is a bispecific antibody.  
     
     
         21 . The method of  claim 20 , wherein said antibody additionally binds to another epitope of CD22.  
     
     
         22 . The method of  claim 1 , wherein said antibody is chimeric.  
     
     
         23 . The method of  claim 1 , wherein said antibody is humanized.  
     
     
         24 . The method of claim I, wherein said antibody is human.  
     
     
         25 .- 28 . (canceled)  
     
     
         29 . The method of  claim 1 , wherein said antibody comprises: 
 (a) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 100 of SEQ ID NO: 9, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:21;    (b) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 97 of SEQ ID NO: 11, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:23;    (c) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 100 of SEQ ID NO: 13, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:25;    (d) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 100 of SEQ ID NO: 15, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:27;    (e) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 98 of SEQ ID NO: 17, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:29; or    (f) a heavy chain comprising a V H  sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 100 of SEQ ID NO: 19, and a light chain comprising a V κ  sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO:31.    
     
     
         30 . (canceled)  
     
     
         31 . The method of  claim 30 , wherein said antibody comprises: 
 (a) a heavy chain comprising a V H  sequence having the sequence of amino acids 1 to 97 of SEQ ID NO: 11 and a light chain comprising a V κ  sequence having the amino acid sequence of SEQ ID NO:23;    (b) a heavy chain comprising a V H  sequence having the sequence of amino acids 1 to 100 of SEQ ID NO: 15, and a light chain comprising a V κ  sequence having the amino acid sequence of SEQ ID NO:27; or    (c) a heavy chain comprising a V H  sequence having the sequence of amino acids 1 to 98 of SEQ ID NO: 17, and a light chain comprising a V κ  sequence having the amino acid sequence of SEQ ID NO:29.    
     
     
         32 - 36 . (canceled)  
     
     
         37 . The method of  claim 29 , wherein said antibody is chimeric or humanized.  
     
     
         38 . The method of  claim 29 , wherein said antibody is human.  
     
     
         39 .- 72 . (canceled)